Vancouver company celebrates reusable food container success
While there are multiple ways to eschew single-use food takeout containers in favour of reusable ones, a Vancouver company says it has moving toward being a major player in the sector.
Reusables.com was founded in 2021 by Jason Hawkins and Anastasia Kiku, then both in their mid-20s, as a way to address the scourge of single-use takeout containers they were seeing piling up in garbage cans, landfills — or even worse — as litter.
"We just don't have any more time to sit and not do something," said Kiku at the time about their concept.
Reusables finds a home at universities, country club
The company provides businesses with reusable containers, which are given to customers at checkout without a deposit. Customers are only charged — between $5 and $10 — if the containers aren't returned to special bins that track them.
It's a simple concept, which others are also doing, but comes with hurdles such as getting customers to change their habits to adopt the system.
Reusables.com says the company recognized its system, now at places such as University of Victoria and Simon Fraser University, is a good fit for where consumers, such as students and staff, return to the same place over and over again.
"It really makes sense as a perfect closed-loop model where everyone is in that location," said Jasper Law, the company's product lead. "It's easy for them to know that they can bring it back to that place."
Reusables also has improved its made-in-Vancouver return bins. Users scan their container to open the bin, meaning it's tamper-proof and can only be filled with Reusables containers.
Law said a successful reusable-container business has to have a high rate of return to be viable.
"What matters in these programs is return rate," he said. "So we are striving to get as close to 100 per cent as possible because every container loss needs to be replaced and that eliminates the value of the program."
West Vancouver's Hollyburn Country Club is now using the Reusables.com system for its 8,000 members.
Officials say member often received food or drink in single-use containers, but used them and discarded them on site, which created a garbage problem.
"So we thought we should look for an alternative solution," said Caitlin Lundy, the club's director of sales and communication.
The club says it's now saving between 8,000 and 10,000 units of paper cups, plastic lids and paper takeout containers per month.
"So the initial cost of the system, it paid for itself within about two months," Lundy said.
Company receives seed funding
Reusables.com captured nearly $4 million in seed funding in April to help it expand further.
"We're thrilled to be backed by the best tech and climate investors as we scale real impact, not just optics," said Hawkins in a release from the company.
"Greenwashing won't solve the waste crisis — technology and execution will."
Single-use item waste is a big problem to tackle in a "take, make waste society," said Denise Philippe, Metro Vancouver's National Zero Waste Council's senior policy adviser.
Metro Vancouver has ambitious goals to reduce this type of waste and commended companies like Reusables.com for trying to make a difference.
"I think there's lots of creativity and innovation that's happening in this space," said Philippe.
"So kudos to both the reuse systems [and] system providers that are out there … scratching their heads … and trying to figure out how to make this work and make it work at scale and make it cost efficient."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors
Workiva Inc. (NYSE:WK) is one of the 11 Best Tech Stocks to Buy On the Dip. On May 29, Workiva Inc. (NYSE:WK) announced the appointment of Astha Malik, Chief Business Officer of Braze, to its board of directors. Malik brings 25 years of experience in driving growth and scaling high-growth SaaS companies. The company also released its Q1 2025 results on May 1. The revenue of $206 million grew 17% year-over-year driven by a 20% increase in subscription and support revenue. Both of these financial indicators surpass management's guidance despite a challenging environment characterized by a cautious buying environment and flat professional services revenue. A software engineer debugging a compliance code on a laptop in a modern office setting. After the earnings release, analyst Alexander Sklar from Raymond James maintained an Overweight rating on Workiva Inc. (NYSE:WK) lowering the price target from $125 to $105. The analyst noted the company showed strong bookings in Q1 however, the tough macroeconomic environment led to a conservative outlook by Raymond James. Regardless, Workiva Inc. (NYSE:WK) maintained its full-year revenue guidance at $864 million to $868 million. Workiva Inc. (NYSE:WK) is a technology company that operates a cloud-based platform that enables organizations to streamline and automate financial, sustainability, and compliance reporting processes. Its SaaS platform combines ERP, HCM, and CRM applications, supporting real-time collaboration and integrated reporting across teams. While we acknowledge the potential of WK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
13 minutes ago
- Yahoo
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a 'Buy' rating and a $72 price target. The research firm remains bullish about the company's prospects owing to the strong potential of its drug candidates. A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The company's partnership with Takeda on Rusfertide to treat polycythemia Vera (PV) and oral IL-23 (icotrokinra) is one of the developments that underscore the research firm's favorable rating. Rusfertide demonstrated strong potential in PV patients in phase 3 trials, affirming its potential to address unmet needs. Citi is especially bullish about adding Rusfertide to existing therapies to expand its use case. In addition, the firm echoed the company's strategic partnership with Johnson & Johnson for multiple inflammation indications. According to Citi, Protagonist Therapeutics shares have outperformed over the past three months, going up by a 40% gain compared to a 2% gain of the S&P 500. It expects the company's combined revenues to climb to $700 million by 2032, above consensus estimates of $680 million. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company that develops peptide-based drugs to treat various diseases, including rare and prevalent ones. Its pipeline includes treatments for blood disorders like polycythemia Vera and inflammatory conditions like ulcerative colitis and psoriasis. While we acknowledge the potential of PTGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Here's Why Globant S.A. (GLOB) Has Trembled More Than 55% This Year
Globant S.A. (NYSE:GLOB) is one of the 11 Best Tech Stocks to Buy On the Dip. The company released its Q1 2025 results on May 15. Globant S.A. (NYSE:GLOB) missed revenue and EPS estimates causing the stock to dip. It posted a revenue of $611.09 million, reflecting 7% growth. However, this was below the market consensus by $10.37 million. The EPS of $1.50 also missed estimates by $0.08. On May 16, Arvind Ramnani analyst at Piper Sandler downgraded Globant S.A. (NYSE:GLOB) from Buy to Hold, while also adjusting the price target from $154 to $116. The analyst noted they had already estimated the macro headwinds, which impacted the revenue growth thereby reducing its estimates. A close-up of an experienced game engineer's hands typing a complex code on a laptop. Impax US Sustainable Economy Fund mentioned Globant S.A. (NYSE:GLOB) in its Q1 2025 investor letter. The fund noted that the company delivered satisfactory results driven by broad demand through various industry verticals and also witnessed revenue growth in new markets. Despite the satisfactory growth, the stock has trembled more than 55.87% on a year-to-date basis mainly due to a complex macroeconomic environment impacting customer spending. The fund anticipates the economic pressure to impact the revenue projections. Management of Globant S.A. (NYSE:GLOB) anticipates second-quarter revenue to be at least $612.0 million, reflecting 4.2% year-over-year growth. Impax US Sustainable Economy Fund stated the following regarding Globant S.A. (NYSE:GLOB) in its Q1 2025 investor letter: 'Globant S.A. (NYSE:GLOB) (Information Technology) is a software solutions provider helping to enhance productivity and drive increasing digital infrastructure in the transition to a more sustainable economy. The stock was down despite delivering satisfactory results, due to broad demand across multiple industry verticals and significant revenue growth in new markets. However, political volatility and macroeconomic pressures in Latin America are expected to affect demand, resulting in slightly lower revenue projections for the upcoming fiscal year.' While we acknowledge the potential of GLOB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio